Biote (BTMD) reported $192M in revenue for fiscal 2025, −2.5% year on year. That ranks #2674 by revenue among 2853 SEC filers and #289 in Healthcare. Net income was $27.0M, a net margin of 14.1%. Revenue has grown 8.4% a year on average since 2021 ($139M then). The fiscal 2025 balance sheet shows $108M in total assets, $24.1M in cash and $95.8M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $192M | −2.5% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $35.6M | +12.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $27.0M | +756.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $35.2M | −22.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $5.0M | −22.0% | FY20252025-12-31 |
| Total assetsAssets | $108M | −12.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$58.5M | +$47.4M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $24.1M | −38.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $95.8M | −5.4% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $44.9M | $2.3M | Open → |
| Q2 20262026-06-30 | $44.2M | −$6.6M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Biote Corp.
- Ticker
- BTMD
- Exchange
- Nasdaq
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 12-31
- CIK
- 0001819253
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KMar 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Strata Critical MedicalSRTA | $197M | $41.3M |
| LifemdLFMD | $194M | −$11.2M |
| Lakeland IndustriesLAKE | $193M | −$25.3M |
| BioteBTMD | $192M | $27.0M |
| Rhythm PharmaceuticalsRYTM | $190M | −$196,539 |
| Maravai LifesciencesMRVI | $186M | −$131M |
| Stoke TherapeuticsSTOK | $184M | −$6.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Biote — Key figures |url=https://companiesranked.com/en/company/biote |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Biote — Key figures. CompaniesRanked. https://companiesranked.com/en/company/bioteBibTeX
@misc{companiesranked-en-company-biote-2026,
author = {{CompaniesRanked}},
title = {{Biote — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/biote}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-106099 · March 13, 2026
{{cite web |title=Biote — Key figures — 10-K (0001193125-26-106099) |url=https://www.sec.gov/Archives/edgar/data/1819253/000119312526106099/btmd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.